Pharmaceutical and Biotechnology companies are challenged with the ability to deliver operational excellence with full traceability and to efficiently manage the ever changing global regulatory environment. License to Cure for BioPharma is an Industry Solution Experience that uniquely provides the ability to accelerate therapeutic development, approval, manufacturing, and supply, in a global landscape by leveraging an extensive, connected and comprehensive regulatory and quality platform.
License to Cure for BioPharma provides digital continuity for organizations to manage the complexity of an ever increasing number of medicinal products with a single version of the truth based on IDMP standards and enables change impact analysis, informed decision making and full IP reuse to deliver quality best practices shifting the paradigm of regulatory as a constraint to regulatory as an asset.
Axendia’s latest white paper: “The Key to Bio-Pharma Transformation” will explore how Pharmaceuitcal and Biotech companies can benefit by adopting a more holistic approach to PLM to accelerate innovation cycles and innovate through digital continuity.
Register now to download the whitepaper.
Transition from a traditional product oriented model to the delivery of therapeutic solutions using a system that enables companies to be more reactive to quickly meet today's market needs.
Spend less time, reduce the risk of non-compliance, improve traceability and accelerate global expansion
Enhance decision-making through real-time views across the lifecycle of innovation
The 3DEXPERIENCE® platform enables businesses to transition from historical and outdated practices to a connected and transformative environment across your extended ecosystem.
Learn how Biogen addressed a challenge that is common with many pharma and biopharmaceutical companies: how to reduce inefficiency and improve the delivery of crucial documentation.
Accelerate therapeutic approval, production, and patient adoption in a global landscape